ENTA

Enanta Pharmaceuticals, Inc. (ENTA) | Rumor.io

Enanta Pharmaceuticals

ENTA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,130

Bullish sentiment (50-day avg)0%

Price to earnings ratio-3.29

Market capitalization367.4M

Earnings per share-2.42

Dividend yield (TTM)—

Revenue (annual)65.3M

Net income (annual)-81.9M

Social

What share of all stock conversation is about ENTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 1

Enanta Pharmaceuticals (ENTA) has announced the pricing of an upsized public offering of 6,500,000 shares of common stock at $10.00 per share.
Jefferies has upgraded Enanta Pharmaceuticals to Buy from Hold on its RSV treatment, raising the target price to $20 from $14.
The stock price of Enanta Pharmaceuticals has doubled after investors digested the implications of data from a readout, despite an initial sell-off due to a misunderstood topline miss.

Generated by AI

Sentiment

Of the messages about ENTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	59.84% -17.73
Bearish	—	—	100% 0	40.16% +17.73

Bullish· Sep 29

$ENTA has been identified as a strong short-term trend breakout with a bullish technical outlook, making it a breakout play.
The company's pioneering small molecule drugs for viral infections and liver diseases, as well as its early-stage immunology pipeline, have been highlighted as key drivers of its growth.
The stock has shown strong momentum, surging past resistance and holding above key levels, with a potential upside of 100-200% if it breaks through $25.

Bearish· Sep 29

The company's RSV drug missed its primary endpoint, causing the stock to tumble.
The stock's recent spike was short-lived, and it's now forming a descending wedge, indicating potential range expansion.
The company's misleading headline and mixed trial results may lead to further price drops, with some predicting a decline to $4-5.

Generated by AI

Topics

Of the messages about ENTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	84.9%
Earnings	—	—	—	2.84%
Analysts	—	—	—	3.06%
Controversies	—	—	—	8.1%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1.09%

Earnings· Aug 7

Enanta Pharmaceuticals (ENTA) reported FQ3 earnings of 97c EPS, missing the Estimize EPS Consensus by 3c.
The company's revenue was $57.26M, also missing the Estimize Revenue Consensus by $0.24M.
ENTA's earnings call is scheduled for today at 4:30pm Eastern, where the company will discuss its Q3 performance.

Analysts· Oct 23

Barclays downgraded Enanta Pharmaceuticals to Underweight with a PT of $16, citing a strong balance sheet and future pipeline.
JMP Securities upgraded Enanta Pharmaceuticals to Outperform with a PT of $32, calling the selloff an overreaction.
JMP Securities set a target price of $32.00 for Enanta Pharmaceuticals, upgrading it to Market Outperform from Market Perform.

Announcements· Oct 1

Enanta Pharmaceuticals has priced an upsized public offering of 6,500,000 shares of common stock at $10.00 per share.
The offering is expected to close on October 2, 2025, with all shares being offered by Enanta Pharmaceuticals.
The company has raised $65 million through this stock offering, with the additional option to sell more shares.

Generated by AI

Community

Of the messages about ENTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	46.67%
Newcomers	—	—	0%	53.33%

Regulars· Sep 29

The company's Phase 2b data for zelicapavir showed clinically meaningful symptom resolution improvements across multiple endpoints, including a 6.7-day benefit in elderly or comorbid patients.
The primary endpoint of time to mild symptoms in the lower respiratory tract was missed, but the study hit on various secondary endpoints, including a significant reduction in RSV VL and reduced risk of hospitalization in high-risk patients.
The company's RSV and immunology programs are seen as having significant value, with one participant noting that the market is ascribing essentially zero value to these programs, and another stating that they are the furthest along for RSV treatment in the US.

Newcomers· Sep 30

The company's stock price surged 91.9% after positive trial data renewed confidence in its liver disease pipeline.
Analysts expect further development milestones to sustain momentum, with 5 out of 7 rating the stock a "Buy" and a median price target of $20.
The stock had fallen 8% after hours following a $50M stock offering, but still has a strong outlook with a 58% increase in the past few days.

Generated by AI

WATERTOWN, Mass., September 01, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September:

29d agoYahoo Finance

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

WATERTOWN, Mass., August 10, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026.

1mo agoYahoo Finance

Also Discussed

Investors talking about ENTA also mention

#	Name	Attention
1	RVNC - Revance Therapeutics, Inc.	——
2	EGRX - Eagle Pharmaceuticals, Inc.	——
3	Agios Pharmaceuticals, Inc.AGIO	0%0
4	BioMarin Pharmaceutical IncBMRN	0%+0
5	ICPT - Intercept Pharmaceuticals, Inc.	——
6	SGEN - Seagen Inc.	——
7	Corcept Therapeutics Inc.CORT	0%new
8	AbbVie Inc.ABBV	0.03%-0.03
9	Rockwell Medical Inc.RMTI	0%new
10	Neurocrine Biosciences, Inc.NBIX	0%new

Enanta Pharmaceuticals, Inc.

Healthcare
Biotechnology

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.

Website

Location

4 Kingsbury Avenue

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about ENTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Oct 1

Enanta Pharmaceuticals (ENTA) has announced the pricing of an upsized public offering of 6,500,000 shares of common stock at $10.00 per share.
Jefferies has upgraded Enanta Pharmaceuticals to Buy from Hold on its RSV treatment, raising the target price to $20 from $14.
The stock price of Enanta Pharmaceuticals has doubled after investors digested the implications of data from a readout, despite an initial sell-off due to a misunderstood topline miss.

Generated by AI

Sentiment

Of the messages about ENTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% 0	59.84% -17.73
Bearish	—	—	100% 0	40.16% +17.73

Bullish· Sep 29

$ENTA has been identified as a strong short-term trend breakout with a bullish technical outlook, making it a breakout play.
The company's pioneering small molecule drugs for viral infections and liver diseases, as well as its early-stage immunology pipeline, have been highlighted as key drivers of its growth.
The stock has shown strong momentum, surging past resistance and holding above key levels, with a potential upside of 100-200% if it breaks through $25.

Bearish· Sep 29

The company's RSV drug missed its primary endpoint, causing the stock to tumble.
The stock's recent spike was short-lived, and it's now forming a descending wedge, indicating potential range expansion.
The company's misleading headline and mixed trial results may lead to further price drops, with some predicting a decline to $4-5.

Generated by AI

Topics

Of the messages about ENTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	84.9%
Earnings	—	—	—	2.84%
Analysts	—	—	—	3.06%
Controversies	—	—	—	8.1%
Macro	—	—	—	0%
Technical Analysis	—	—	—	1.09%

Earnings· Aug 7

Enanta Pharmaceuticals (ENTA) reported FQ3 earnings of 97c EPS, missing the Estimize EPS Consensus by 3c.
The company's revenue was $57.26M, also missing the Estimize Revenue Consensus by $0.24M.
ENTA's earnings call is scheduled for today at 4:30pm Eastern, where the company will discuss its Q3 performance.

Analysts· Oct 23

Barclays downgraded Enanta Pharmaceuticals to Underweight with a PT of $16, citing a strong balance sheet and future pipeline.
JMP Securities upgraded Enanta Pharmaceuticals to Outperform with a PT of $32, calling the selloff an overreaction.
JMP Securities set a target price of $32.00 for Enanta Pharmaceuticals, upgrading it to Market Outperform from Market Perform.

Announcements· Oct 1

Enanta Pharmaceuticals has priced an upsized public offering of 6,500,000 shares of common stock at $10.00 per share.
The offering is expected to close on October 2, 2025, with all shares being offered by Enanta Pharmaceuticals.
The company has raised $65 million through this stock offering, with the additional option to sell more shares.

Generated by AI

Community

Of the messages about ENTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	46.67%
Newcomers	—	—	0%	53.33%

Regulars· Sep 29

The company's Phase 2b data for zelicapavir showed clinically meaningful symptom resolution improvements across multiple endpoints, including a 6.7-day benefit in elderly or comorbid patients.
The primary endpoint of time to mild symptoms in the lower respiratory tract was missed, but the study hit on various secondary endpoints, including a significant reduction in RSV VL and reduced risk of hospitalization in high-risk patients.
The company's RSV and immunology programs are seen as having significant value, with one participant noting that the market is ascribing essentially zero value to these programs, and another stating that they are the furthest along for RSV treatment in the US.

Newcomers· Sep 30

The company's stock price surged 91.9% after positive trial data renewed confidence in its liver disease pipeline.
Analysts expect further development milestones to sustain momentum, with 5 out of 7 rating the stock a "Buy" and a median price target of $20.
The stock had fallen 8% after hours following a $50M stock offering, but still has a strong outlook with a 58% increase in the past few days.

Generated by AI

Enanta Pharmaceuticals

Social

Oct 1

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 7

Analysts· Oct 23

Announcements· Oct 1

Regulars· Sep 29

Newcomers· Sep 30

Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta earnings missed by $0.17, revenue fell short of estimates

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Also Discussed

Enanta Pharmaceuticals, Inc.

Company Information

Location

Enanta Pharmaceuticals stock rating reiterated at Buy by H.C. Wainwright

Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta earnings missed by $0.17, revenue fell short of estimates

Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Also Discussed

Social

Oct 1

Bullish· Sep 29

Bearish· Sep 29

Earnings· Aug 7

Analysts· Oct 23

Announcements· Oct 1

Regulars· Sep 29

Newcomers· Sep 30